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Monocytes from patients with 
Primary Ciliary Dyskinesia show 
enhanced inflammatory properties 
and produce higher levels of pro-
inflammatory cytokines
M. Cockx1, M. Gouwy1, P. Ruytinx1, I. Lodewijckx1, A. Van Hout1, S. Knoops1, N. Pörtner1,  
I. Ronsse1, L. Vanbrabant1, V. Godding2, K. De Boeck3, J. Van Damme1, M. Boon3 & S. Struyf1
Patients with Primary Ciliary Dyskinesia (PCD) suffer from recurrent upper and lower airway infections 
due to defects in the cilia present on the respiratory epithelium. Since chronic inflammatory conditions 
can cause changes in innate immune responses, we investigated whether monocytes isolated from 
the peripheral blood of pediatric PCD patients respond differently to inflammatory stimuli, compared 
to monocytes from healthy children and adults. The receptor for C5a (C5aR) was upregulated in PCD, 
whereas expression levels of the leukocyte chemoattractant receptors CCR1, CCR2, CCR5, BLT1 and 
FPR1 on PCD monocytes were similar to those on monocytes from healthy individuals. Also in vitro 
migration of PCD monocytes towards the ligands of those receptors (CCL2, fMLP, C5a and LTB4) 
was normal. Compared to healthy children, PCD patients had a higher percentage of the non-classic 
monocyte subset (CD14+CD16++) in circulation. Finally, PCD monocytes produced higher levels of 
pro-inflammatory cytokines (IL-1β and TNF-α) and chemokines (CCL3, CCL5, CCL18 and CCL22) in 
response to LPS, peptidoglycan and/or dsRNA stimulation. These data suggest that monocytes might 
exacerbate inflammatory reactions in PCD patients and might maintain a positive feedback-loop 
feeding the inflammatory process.
Primary Ciliary Dyskinesia (PCD) is an autosomal inherited recessive disorder caused by mutations leading to 
structural and/or functional defects of motile cilia. It is a rare disease with an incidence of 1/10,000–1/20,000 
individuals1–3. In the respiratory tract, motile cilia are essential in protecting the lungs from injury and infection 
by upward transport of the mucus, in which harmful microorganisms and particles are captured. This process is 
called mucociliary clearance and its deficiency, due to ineffective movement of the motile cilia, causes recurrent 
infections of the upper and lower airways in PCD patients4.
To date, about 35 genes have been linked to PCD, mostly leading to loss or abnormal functioning of the 
energy-producing ciliary dynein proteins5–7. About 30 percent of the PCD patients, however, carry a yet unknown 
gene mutation. The genetic heterogeneity is linked to the complex structure of motile cilia, consisting of more 
than 250 different proteins8. This results in heterogeneity of symptoms and disease severity, which challenges 
both diagnosis and treatment of PCD. Management of PCD aims to control the recurrent airway infections and 
maintain lung function by administering antibiotics and stimulating airway clearance, respectively9. To date, few 
studies have been performed to reveal the pathophysiologic processes in PCD other than ciliary motion that may 
contribute to the disease.
The aim of this study is to unravel the role of the innate immune system as a possible factor of heterogene-
ity in disease severity in PCD. Indeed, in cystic fibrosis (CF), another lung disease characterized by impaired 
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mucociliary clearance, several aspects of the innate immune responses are abnormal10. The CFTR gene affected 
in CF is expressed in neutrophils and in monocytes and leads to aberrant leukocyte responses, but also second-
ary effects of the chronic inflammation on innate leukocyte function have been demonstrated. PCD and CF are 
both characterized by a prominent neutrophilic lung infiltrate, which might be caused by overproduction of the 
chemokine CXCL811,12. Despite the high neutrophil count, CF and PCD patients suffer from recurrent bacte-
rial airway infections. To clear those infections, monocytes are also crucial as they are key players in detecting 
pathogens and activating other blood leukocytes (e.g. neutrophils) by secreting cytokines and chemokines13–15. 
Chemokines or chemotactic cytokines are first secreted by resident cells at the site of infection, to attract addi-
tional monocytes and other phagocytes to combat the infection. Specific chemokines (CCL and CXCL), recog-
nized by monocytes via their corresponding chemoattractant receptors (CCR and CXCR), generate a chemokine 
concentration gradient along which monocytes migrate to reach the site of infection. Other chemoattractants 
recognizing different chemoattractant receptors, such as N-formylmethionine-leucyl-phenylalanine (fMLP), 
leukotriene B4 (LTB4) and complement component 5a (C5a) assist in guiding and activating monocytes. 
Chemoattractants activate immune cells by binding to their corresponding chemoattractant receptors. These 
receptors are 7-transmembrane G protein-coupled receptors (GPCR) and altered expression has been implicated 
in many inflammatory diseases, e.g. rheumatoid arthritis and inflammatory bowel disease16. Chemoattractants 
are thus essential for a properly functioning immune system17,18. More recently, monocytes have been recognized 
as a phenotypically and functionally heterogeneous population15. The monocyte subtypes can be differentiated 
from each other according to their CD14 and CD16 expression. In some inflammatory disorders, an altered ratio 
of classic (CD14++CD16−), intermediate (CD14++CD16+) and non-classic monocytes (CD14+CD16++) 
in the blood circulation has been associated with disease progression19,20, but no information is available on the 
relative abundance of the different monocyte subsets in PCD.
Therefore, we decided to investigate whether monocytes from PCD patients are affected functionally, either 
through the PCD gene defect or through the chronic inflammatory milieu. We thus first measured the chemoat-
tractant receptor expression on monocytes of PCD patients and their capability to respond to their ligands CCL2, 
LTB4, fMLP and C5a. Further, we examined the phagocytic capacity and the regulation of adhesion molecules on 
monocytes of PCD patients. We also defined the number of classic, intermediate and non-classic monocytes in 
the blood circulation of PCD patients versus healthy controls. Finally, we determined levels of several cytokines 
produced by activated PCD monocytes.
Results
Patient characteristics. Thirty six patients with PCD (range 2–26 years, median age 13 years; for details see 
Table 1) were enrolled in this study between June 2012 and November 2016 at the University hospitals of Leuven. 
Patients were only included when they were clinically stable (no change in cough or sputum, no fever, no change 
in therapy for a period of at least 2 weeks, change in forced expiratory volume in 1 second (FEV1) < 10% since the 
last measurement). Diagnosis was made based on a combination of tests: electron microscopy to detect ultras-
tructural cilium changes, video-microscopy analysis to evaluate ciliary motility, nasal nitric oxide measurements 
and genetic analysis. Electron microscopy of the cilia showed abnormalities in 20 and normal ultrastructure in 16 
patients. All patients displayed abnormal ciliary activity after cell culture of nasal or bronchial biopsies. Genetic 
analysis confirmed disease causing mutations in 24 patients, did not provide evidence for mutations in 7 patients 
and was not performed in 5 patients. Because previous studies observed differences in chemotaxis of monocytes 
between infants (younger than 2 years) and adults21, we also included a pediatric control group in these exper-
iments. The adult controls were indispensable as reference for both PCD and healthy children, because testing 
of healthy children and PCD patients on the same day was impossible. We rather preferred this approach than 
performing functional assays with frozen cells.
Monocytes of PCD patients show increased C5aR expression. We investigated the expression of 
several GPCR chemoattractant receptors on monocytes of PCD patients (PCD), age-matched pediatric controls 
(Ped CO) and healthy adult controls (Ad CO). The expression of CCR1, CCR2, CCR5, FPR1 (fMLP receptor), 
BLT1 (the LTB4 receptor) and C5aR (C5a receptor) on adult and pediatric controls was similar (Fig. 1). C5aR 
expression was significantly higher on monocytes of PCD patients compared to both control groups (p < 0.05, 
p < 0.01) (Fig. 1f). The key monocyte chemokine receptors (CCR1 and CCR2) were expressed at a similar level 
on monocytes from PCD patients and healthy adults/children (Fig. 1a,b). Finally, the expression levels of CCR5, 
FPR1 and BLT1 were also normal on PCD monocytes (Fig. 1c–e).
Altered chemoattractant receptor expression on monocytes from PCD patients does not 
influence the migration capacity. We next investigated whether the migration of monocytes from PCD 
patients is affected (Fig. 2). We did not observe significant differences between migration of cells from Ped CO 
and Ad CO. We observed that the altered C5aR expression on monocytes from PCD patients had no effect on 
the migration capacity to C5a (Fig. 2b). Migration towards the CCR1/CCR5 ligand CCL3L1 was tested on cells 
from only a few patients (n = 7) and did also not differ from healthy adults/children (data not shown). The chem-
otactic response to CCL2, LTB4 and fMLP was similar for monocytes of PCD patients and healthy individuals 
(Fig. 2a,c,d).
Circulating monocytes from PCD patients show normal CD62L, but altered CD15 expression 
upon stimulation with fMLP. To reach the site of infection, leukocytes need to extravagate through the 
endothelium, a process regulated by successive interactions between adhesion molecules on leukocytes and 
the blood endothelium. We measured the expression of the selectin CD62L and of CD15 (a LewisX carbohy-
drate antigen that binds selectins on endothelium) on monocytes in whole blood by flow cytometry (Fig. 3). 
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Chemoattractant-activation of monocytes leads to upregulation of CD15 and downregulation of CD62L to allow 
subsequent integrin-mediated firm adhesion on the blood endothelium. fMLP and CCL2 are acknowledged 
stimuli of leukocyte adhesion to the endothelium22–26. First, we analyzed basal expression of those molecules on 
unstimulated monocytes (Fig. 3a). The expression levels were calculated relative to the levels on the monocytes 
from the Ad CO. The expression levels of CD15 and CD62L were similar on resting monocytes from healthy 
adults/children and PCD patients. fMLP caused a more pronounced effect (upregulation of CD15 and downreg-
ulation of CD62L) than CCL2 (Fig. 3b,c). Upon fMLP stimulation, we measured significantly less upregulation 
of CD15 on PCD monocytes compared to both healthy control groups (p < 0.01) (Fig. 3b, CD15). CCL2 stimu-
lation, however, resulted in no significant differences in up- or downregulation of adhesion molecules among the 
three groups (Fig. 3c). However, it must be noted that CD15 expression on monocytes from healthy individuals 
was not significantly altered in response to CCL2 stimulation.
Monocytes from PCD patients have similar phagocytic capacities compared to healthy con-
trols. One of the main activities executed by monocytes during infection and inflammation is phagocytosis. 
We tested the phagocytic capacity of monocytes with fluorescent beads coated with S. aureus (Fig. 4). Monocytes 
from PCD patients displayed a lower capacity to phagocytose compared to Ad CO (not significant), but we 
observed similarly reduced phagocytic capacity in Ped CO.
Higher numbers of non-classic monocytes are present in the circulation of PCD patients com-
pared to age-matched healthy controls. More recently, different subpopulations in peripheral blood 
monocytes have been defined19. We analyzed by flow cytometry whether a shift between those monocyte sub-
groups can be observed in PCD patients (Fig. 5). The three groups showed a statistically similar number of 
CD14++CD16− monocytes, although somewhat higher numbers were detected in Ped CO (Fig. 5a, Ped CO 
versus Ad CO), as already described before27. As a consequence, children tend to have lower percentages of circu-
lating non-classic CD14+CD16++ monocytes compared to adults. However, the non-classic CD14+CD16++ 
monocyte subset was significantly increased in PCD patients compared to Ped CO (p < 0.05) (Fig. 5c).
PCD
Healthy adult 
controls
Healthy pediatric 
controls
Female/Male No. 18/18 14/5 15/6
Age, median (range) in years 13 (2–26) 28.3 (23–41) 9.5 (4–18)
Ultrastructural defect
Normal ultrastructure 16/36
ODA 16/36
IDA 1/36
CP 3/36
Ciliary aplasia 1/36
Clinical features
Situs inversus 13/36
Bronchiectasis 22/36
FVC, median (range) (%) 96.5 (65–122)
FEV1, median (range) (%) 91 (38–113)
Laboratory features, median (range)
WBC count (/µl) 7300 (4640–17240)
CRP (mg/dl) 1.1 ( < 0.3–4.9)
Sputum bacteria
P. aeruginosa 3/36
H. influenzae 7/36
S. aureus 6/36
S. pneumoniae 1/36
M. catarrhalis 2/36
Treatment
Oral antibiotics 5/36
Intravenous immunoglobulins 2/36
Subcutaneous immunoglobulins 1/36
Azithromycin 10/36
Inhaled steroids 13/36
Table 1. Patient characteristics. CP: central pair abnormalities; CRP: C-reactive protein; FEV1: forced 
expiratory volume after 1 second; FVC: forced vital capacity; IDA: inner dynein arm deficiency; ODA: outer 
dynein arm deficiency; WBC: white blood cells.
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PBMCs from PCD patients produce more pro-inflammatory cytokines and chemokines com-
pared to healthy controls. Finally, we investigated the capability of PCD peripheral blood mononuclear 
cells (PBMCs) to produce cytokines and chemokines to stimulate and attract other immune cells to the site of 
infection. We stimulated PBMCs from PCD patients, Ped CO and Ad CO with the inflammatory mediators 
LPS, dsRNA (PIC), conA, PGN and IL-1β. The induced cytokines and chemokines present in the supernatants 
after 24 h of stimulation were measured by ELISA (Figs 6,7). In response to the TLR4 ligand LPS, PBMCs from 
PCD patients secreted significant higher levels of TNF-α (p < 0.01) (Fig. 6a), IL-1β (p < 0.05) (Fig. 6b), CCL3 
(p < 0.001) (Fig. 7a) and CCL18 (p < 0.0001) (Fig. 7c). We also measured higher levels of CCL22 (Fig. 7d) in 
response to LPS treatment, but the production was not significantly increased. In response to the TLR3 ligand 
dsRNA (PIC), which was the weakest inducer, we measured higher CCL22 levels (p < 0.05) (Fig. 7d) in super-
natants of PCD PBMCs. Higher CCL5 (Fig. 7b) and CCL18 (p < 0.01) (Fig. 7c) levels were detected in the con-
ditioned media of PCD PBMCs compared to Ped CO cultures upon conA stimulation. Addition of the TLR2 
ligand PGN led to elevated production of TNF-α (Fig. 6a), CCL3 (p < 0.01) (Fig. 7a), CCL18 (p < 0.01) (Fig. 7c) 
and CCL22 (p < 0.05) (Fig. 7d) in PBMC cultures of PCD compared to Ped CO. Finally, upon IL-1β stimulation 
increased CCL5 (Fig. 7b), CCL18 (p < 0.05) (Fig. 7c) and CCL22 (Fig. 7d) concentrations were measured in 
supernatants of PBMCs isolated from PCD patients. Interestingly though, PBMCs from PCD patients and Ped 
CO tended to produce lower amounts of IL-10 (an anti-inflammatory cytokine) compared to Ad CO (Fig. 6c). 
Overall, we can conclude that upon stimulation in vitro, PBMCs from PCD patients produce higher levels of 
pro-inflammatory cytokines compared to PBMCs of healthy controls. The chemokine levels produced, were high 
enough (10 ng/ml range) to trigger a biological response, except for CCL18 of which the maximal production 
reached 0.1 ng/ml (data not shown).
Discussion
Due to ineffective mucociliary clearance in the airways, PCD patients suffer from recurrent infections in the 
upper and lower airways. Today, PCD patients are treated analogously to patients with CF, which is both geneti-
cally and symptomatically a different disease12. Our hypothesis is that besides ineffective clearance of pathogens, 
an affected innate immune system contributes to the recurrent airway infections in PCD patients. Monocytes are 
key players during infection by detecting microbial molecules, attracting and stimulating other immune cells and 
serving as a link to the adaptive immune system15. Boon et al.28 reported a link between PCD and humoral immu-
nodeficiency disorder (HID), a rare disease characterized by hypogammaglobulinemia, defective specific anti-
body production and an increased susceptibility to infections. They found that in a large cohort of PCD patients, 
6.5% of the patients also suffered from HID, suggesting that a common pathophysiological pathway results in 
Figure 1. Chemoattractant receptor expression levels on monocytes of PCD patients and healthy controls. 
Expression levels of (a) CCR1, (b) CCR2, (c) CCR5, (d) FPR1, (e) BLT1 and (f) C5aR on monocytes of PCD 
patients (PCD), age-matched healthy pediatric controls (Ped CO) and healthy adult controls (Ad CO) were 
measured by flow cytometry. The chemoattractant receptor expression levels (mean fluorescence intensity, MFI) 
were normalized to the levels on monocytes of the reference Ad CO (%). Each dot represents the normalized 
MFI of one patient or healthy control (*p < 0.05, **p < 0.01; Mann Whitney U-test).
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both disorders28. These results provide a first indication of an abnormal immune system in PCD patients. In this 
paper, we studied the chemotactic and antibacterial properties of peripheral blood monocytes of PCD patients. To 
the best of our knowledge, this is the first in depth study of peripheral blood monocytes from patients with PCD.
First, we found higher C5aR expression on PBMCs of PCD patients compared to both healthy control groups. 
The receptors that bind the main chemokine attractants of monocytes (CCR1 for CCL3 and CCR2 for CCL2) that 
mediate monocyte recruitment to sites of infection were equally expressed on the monocytes of the three groups.
Chemokine and chemoattractant receptor expression are tightly regulated to prevent aberrant functioning 
of the innate immune system29,30. We did not observe altered chemotactic migration of PCD monocytes towards 
C5a (ligand of C5aR) compared to the healthy control groups. Neither did we measure distinctive chemotactic 
migration towards the other chemoattractants. Further research is necessary to elaborate if these elevated recep-
tor expression levels have a potential role in the pathogenesis of PCD lung disease. Aberrant C5aR expression on 
leukocytes has been associated with several inflammatory diseases31.
We also examined the expression of the adhesion molecules CD15 and CD62L to investigate the capacity of 
monocytes from PCD patients to adhere to the endothelium. Baseline expression on non-stimulated monocytes 
was similar in the healthy adults, healthy children and PCD patients. Activation of monocytes leads to down-
regulation of selectins to allow firm adhesion on the endothelium. We observed that fMLP provoked higher 
CD15 upregulation and CD62L downregulation compared to CCL2. After fMLP stimulation, monocytes from 
PCD patients displayed reduced CD15 upregulation. Since CCL2 did not significantly alter CD15 expression on 
healthy monocytes, it is not clear whether moderated CD15 upregulation is a general property of PCD monocytes 
or is specific for their response to fMLP32.
Phagocytosis is a key defense mechanism of monocytes during infection and inflammation. Pathogens and 
cell debris can be cleared by monocytes to prevent further damage to tissues13. We speculated that a reduced 
Figure 2. Monocytes from PCD patients and healthy controls are equally responsive in migration assays. 
Chemotactic responses of monocytes from PCD patients (PCD), age-matched healthy pediatric controls (Ped 
CO) and healthy adult controls (Ad CO) to (a) CCL2 (10 ng/ml), (b) C5a (10 ng/ml), (c) LTB4 (10-8 M) and 
(d) fMLP (10-8 M) were assessed in the Boyden chamber chemotaxis assay. The chemotactic index (CI; average 
number of migrated cells in response to the chemoattractant divided by the average number of spontaneously 
migrated cells) was used to express the chemotactic response. The CIs were normalized to the CI of the 
reference Ad CO (%). No statistical differences in chemotactic responses of monocytes from PCD patients and 
monocytes of healthy controls were detected (Mann Whitney U-test).
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Figure 3. Circulating monocytes of PCD patients show reduced CD15 upregulation upon fMLP stimulation. 
The expression levels of the selectin ligand CD15 and the selectin CD62L on monocytes of PCD patients (PCD), 
age-matched healthy pediatric controls (Ped CO) and healthy adult controls (Ad CO) were measured by flow 
cytometry, either in (a) buffer (untreated) or upon (b) 10−8 M fMLP or (c) 300 ng/ml CCL2 stimulation. The 
expression levels were normalized to the expression level of the reference Ad CO (%). The expression levels 
in b and c were normalized to the expression levels in buffer conditions. ‘$’Indicate significant differences 
in expression levels of the adhesion molecule on the monocytes in response to fMLP or CCL2 stimulation 
compared to buffer treatment. ‘*’Indicate differences between the PCD patients and a control group (**p < 0.01; 
Mann Whitney U-test).
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phagocytic capacity of monocytes from PCD patients could contribute to the chronic inflammatory milieu 
observed in the airways of PCD patients. We assessed phagocytosis by using Staphylococcus aureus labeled flu-
orescent beads and measured intake of the beads by flow cytometry. We observed lower intake of the beads by 
PBMCs from PCD patients compared to Ad CO (not significant), but similarly lower uptake was also measured 
with PBMCs from some Ped CO. This could indicate that the capacity to phagocytose pathogens and debris by 
monocytes is age-dependent. Lower phagocytic capacity of monocytes from children has been detected before, 
although these were neonates, age 0–11 months old33. In the latter study, also healthy children between 1–12 years 
old were included and no difference in phagocytic capacity was observed compared to healthy adult controls.
To further explore the characteristics of monocytes from PCD patients, we examined the proportion of mono-
cyte subtypes in the total monocyte population34. Classic monocytes (CD14++CD16−) express high levels of 
CCR2 and low levels of CX3CR1, non-classic monocytes (CD14+CD16++) lack CCR2 and express high lev-
els of CX3CR1, whereas the intermediate monocytes (CD14++CD16+) express both CCR2 and CX3CR1. As 
CX3CR1 expression, the receptor for endothelium-bound CX3CL1, is higher on CD16+ and CD16++ mono-
cytes, those subsets are thought to adhere and extravagate more efficiently compared to CD16- monocytes35,36. 
Functionally, non-classic monocytes are considered as patrollers of the vascular endothelium, both at steady 
state and during inflammation, and remove debris37. Like classic monocytes, also intermediate monocytes dis-
play pro-inflammatory characteristics, e.g. high pro-inflammatory cytokine secretion (IL-1β and TNF-α) and 
high MHC II expression on the cell membrane. Indeed, intermediate monocytes express significantly higher 
levels of TLRs 2, 4 and 5 as compared to the other two subsets. Previous studies have already described a lower 
CD16+ monocyte proportion in the blood circulation of children compared to adults27, which was confirmed 
in our study. The non-classic monocytes (CD14+CD16++) were significantly elevated in the blood circulation 
of PCD patients compared to Ped CO (p < 0.05). CD16+ and CD16++ monocyte subset increase was already 
observed in other inflammatory diseases, for example in patients with sepsis and rheumatoid arthritis, and is 
associated with disease progression19,38. In contrast to classic and intermediate monocytes, CD14+CD16++ cells 
produce only low cytokine levels under basal conditions, but respond well to TLR7/8 stimuli.
The last monocyte function examined in this study was the release of cytokines by activated monocytes, an 
important process in the regulation of the immune defense. We observed that stimulation with PGN provoked the 
most differential secretion of pro-inflammatory cytokines (significantly higher CCL3, CCL18 and CCL22 levels 
produced) by PBMCs from PCD patients compared to Ped CO. Also LPS, conA and IL-1β stimulation resulted 
in increased production of pro-inflammatory cytokines by PBMCs of PCD patients. These results suggest that in 
PCD patients likely more leukocytes are attracted to the site of infection through increased cytokine release by 
monocytes compared to age-matched Ped CO and Ad CO. This could contribute to the chronic inflammation 
observed in PCD patients. Indeed, increased CXCL8 sputum levels were measured in PCD patients11.
An advantage of this study was that we were able to include healthy pediatric controls, as there are only lim-
ited data available on pediatric values for monocyte function and chemoattractant receptor expression levels in 
function of age. In this way, we could demonstrate that for most functions, there is no difference between adults 
and children, although we confirmed some previously reported differences. Inclusion of a disease control group 
would better indicate whether our findings are specific for PCD. Cystic fibrosis (CF) would have been the most 
relevant disease control group, as both PCD and CF suffer from chronic neutrophilic inflammation in the lungs 
due to inefficient mucociliary clearance. However, monocytes lacking the CF transmembrane conductance reg-
ulator show reduced adhesion capacity, chemotactic migration and phagocytosis39,40. Consequently, this group 
Figure 4. The phagocytic capacity of monocytes from patients with PCD is similar to that of monocytes 
from healthy controls. The phagocytic capacity of monocytes from PCD patients (PCD), age-matched healthy 
pediatric controls (Ped CO) and healthy adult controls (Ad CO) was assessed by using Staphylococcus aureus 
labeled beads. The fluorescence intensity of these beads increases when taken up in the acid phagolysosomes 
of phagocytes. The fluorescence signal of the beads was measured by flow cytometry. The uptake of S. aureus 
labeled beads by monocytes from healthy children and PCD patients was expressed relative to the uptake by 
monocytes of the reference Ad CO (%). No significant difference in phagocytosis was detected between the 
monocytes of the PCD patients and the healthy controls (Mann Whitney U-test).
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would not be a good disease control. Patients with non-CF bronchiectasis also share some characteristics with 
PCD, but this group is very heterogeneous and some of these patients might suffer from an unknown underlying 
immune deficiency. Finally, asthma is rather an eosinophilic disorder, and has a completely different pathophysi-
ology. Therefore, we believe that inclusion of an appropriate disease control group is not feasible.
To conclude, this study examined several characteristics of peripheral blood monocytes from PCD patients 
and observed differential expression of C5aR and adhesion molecules, an increased proportion of non-classical 
monocytes and higher production of pro-inflammatory cytokines upon stimulation. These results suggest that 
monocytes of patients with PCD show pro-inflammatory characteristics and can contribute to the chronic 
inflammation observed in PCD patients.
Material and Methods
Patients. We included patients between 2 and 26 years old between June 2012 and November 2016 (Table 1). 
Patients with an established diagnosis of PCD were recruited at the time of routine follow-up at the University 
of Leuven (KUL) and Université Catholique de Louvain (UCL). The diagnosis was based on the current gold 
standard for diagnosis of PCD: structural and functional evaluation of the cilia on a nasal or bronchial biopsy 
specimen, performed in the KU Leuven Laboratory of Ciliary Function41. All patients were clinically stable at the 
time of blood collection. To compare the data of PCD patients and healthy controls, both age-matched pediatric 
controls (Ped CO) (4–18 years, 21 individuals) and adult controls (Ad CO) (23–41 years, 19 individuals) were 
included. Healthy volunteers (adult personnel or their children) were recruited from the Laboratory of Molecular 
Immunology, the Laboratory of Immunobiology (Rega Institute, University of Leuven) and the staff of Pediatric 
Figure 5. Comparison of the ratio of monocyte subpopulations in the blood circulation of PCD patients and 
healthy controls. The number of (a) classic (CD14++CD16−), (b) intermediate (CD14++CD16+) and (c) 
non-classic (CD14+CD16++) monocytes in the blood circulation of PCD patients (PCD), age-matched 
healthy pediatric controls (Ped CO) and healthy adult controls (Ad CO) was determined by flow cytometry. 
The proportion of each monocyte subpopulation was calculated by dividing the number of monocytes in one 
subpopulation by the total number of detected monocytes (*p < 0.05; Mann Whitney U-test).
Figure 6. PBMCs from PCD patients produce more pro-inflammatory cytokines (TNF-α and IL-1β) compared 
to PBMCs from pediatric healthy controls. PBMCs from PCD patients (PCD), age-matched healthy pediatric 
controls (Ped CO) and healthy adult controls (Ad CO) were cultured and stimulated with LPS (5 µg/ml), dsRNA 
(PIC; 10 µg/ml), conA (10 µg/ml) or PGN (1 µg/ml) at 37 °C for 24 h. By sandwich ELISAs, (a) TNF-α, (b) IL-1β 
and (c) IL-10 levels were measured in the supernatants. The cytokine levels are expressed relative to the cytokine 
levels of the reference Ad CO (equal to 100%, not shown) (*p < 0.05, **p < 0.01; Mann Whitney U-test).
www.nature.com/scientificreports/
9SCIentIFIC REPORTS | 7: 14657  | DOI:10.1038/s41598-017-15027-y
Pulmonology. Adult controls were also included since it was impossible to process blood samples of PCD patients 
and age-matched pediatric controls on the same day. Blood samples from PCD and healthy controls were always 
taken at the most 15 minutes apart, and were processed simultaneously. In most figures, data of adult controls are 
equated to 100% so that the results of the pediatric controls and PCD patients could be compared to each other.
The study was approved by the Ethical Committee of the University Hospital of Leuven (S57236[ML11095]) 
and all patients/parents signed informed consent. All experiments were performed in accordance with relevant 
European guidelines and regulations.
Reagents. Anti-CD14 [PE mouse anti-human, clone M5E2], anti-CD16 [PE mouse anti-human, clone 
3G8], anti-CCR1 [Alexa Fluor 647 mouse anti-human CD191, clone 53504], anti-CCR2 [Alexa Fluor 647 
mouse anti-human CD192, clone 48607], κ Isotype Control Alexa Fluor 647 [mouse IgG2b, clone 27–35], 
anti-BLT1 [mouse anti-human, clone 14F11], anti-FPR1 [mouse anti-human, clone 556015], anti-C5aR [mouse 
anti-human, clone D53–1472] and polyclonal PE goat anti-mouse were purchased from BD Biosciences (Temse, 
Belgium). Anti-CCR5 [mouse anti-human, clone 45531] was purchased from R&D Systems (Abingdon, UK). 
Anti-CD15 [FITC mouse anti-human, clone HI98] and anti-CD62L (L-selectin) [APC mouse anti-human, clone 
DREG-56] were obtained from eBioscience (Vienna, Austria). Anti-CD14 [APC mouse anti-human, clone M5E2] 
and APC anti-mouse IgG2a isotype control [clone MOPC-173] were obtained from Biolegend (San Diego, USA). 
LTB4 and recombinant human CCL2 were bought from Peprotech (Rocky Hill, NY), fMLP and recombinant C5a 
from Sigma (St. Louis, USA).
Figure 7. PBMCs from PCD patients produce more pro-inflammatory chemokines (CCL3, CCL18 and 
CCL22) compared to PBMCs from pediatric healthy controls. PBMCs from PCD patients (PCD), age-matched 
healthy pediatric controls (Ped CO) and healthy adult controls (Ad CO) were cultured and stimulated with LPS 
(5 µg/ml), dsRNA (PIC; 10 µg/ml), conA (10 µg/ml), PGN (1 µg/ml) or IL-1β (100 ng/ml) at 37 °C for 24 h. By 
sandwich ELISAs, (a) CCL3, (b) CCL5, (c) CCL18 and (d) CCL22 levels were measured in the supernatants. 
The cytokine levels are expressed relative to the chemokine levels produced by PBMCs from the reference Ad 
CO (equal to 100%, not shown). (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; Mann Whitney U-test).
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Isolation of PBMCs. Blood samples were collected in EDTA+ tubes. PBMCs were isolated from whole 
blood by density gradient centrifugation with Ficoll-sodium diatrizoate (Lymfoprep, Axis-Shield PoC AS, Oslo, 
Norway) (400 × g, 30 min, 20 °C, without break). As such, PBMCs were separated from the red blood cells and 
neutrophils according to their density. The top layer contained both PBMCs and plasma and after collecting 
the PBMCs, they were washed twice with Dulbecco’s phosphate buffered saline (DPBS without Ca2+ and Mg2+; 
Lonza, Bazel, Switzerland) and counted in a hemocytometer.
Flow cytometry. To measure and compare the expression of chemoattractant receptors on PBMCs of PCD 
patients and healthy controls, flow cytometry was used. PBMCs [3 × 105 cells, diluted in FACS buffer (DPBS + 2% 
Fetal Bovine Serum (FBS; Life Technologies))] were stained with the following monoclonal antibodies: unlabe-
led anti-CCR5, anti-FPR1 and anti-C5aR; PE-labeled anti-CD16 and anti-BLT1; APC-labeled anti-CD14; Alexa 
647-labeled anti-CCR1 and anti-CCR2. The cells were incubated with the antibodies for 30 min and afterwards 
washed 3 times with FACS buffer. Cells incubated with unlabeled antibodies were subsequently stained with goat 
anti-mouse PE-labeled antibody and again incubated for 30 min on ice. After 3 additional washing steps, the cells 
were fixed with FACS buffer containing 0.4% paraformaldehyde. Cell suspensions were applied to a FACSCalibur 
flow cytometer (BD Biosciences) and the results were analyzed by CellQuest software (BD Biosciences). Results 
represent expression on monocytes because a gate was set around the CD14-positive cells.
Boyden microchamber chemotaxis assay. PBMC migration was measured in 48-well Boyden micro-
chambers (Neuro Probe, Gaithersburg, MD, USA). The chemoattractants (CCL2, LTB4, fMLP and C5a) were 
diluted with Hanks’ balanced salt solution (HBSS; Life Technologies) containing 1 mg/ml human serum albu-
min (HSA; Belgian Red Cross). The lower wells of the Boyden microchambers were filled in triplicate with the 
diluted chemoattractants. The dilution buffer (HBSS + HSA) was used as control to assess spontaneous migra-
tion. PBMCs (2 × 106 cells/ml, diluted in HBSS + HSA) were added in the upper wells, which were separated 
from the lower wells by a polyvinylpyrrolidone (PVP) polycarbonate membrane (5 µm pore size; GE Water & 
Process Technologies, Manchester, UK) and incubated at 37 °C, 5% CO2 for 2 h. These conditions favor monocyte 
migration, rather than lymphocyte migration. After incubation and treatment of the chemotaxis membrane with 
Hemacolor solutions (Merck, Darmstadt, Germany), the migrated cells were counted microscopically (500 x 
magnification) in 10 high power fields/well. The chemotactic index (CI) was calculated by dividing the average 
number of migrated cells in response to the chemoattractant by the average number of spontaneously migrated 
cells. A relative chemotactic index (CI) was used wherein the CI of the adult control tested on the same day as 
PCD patients or pediatric controls is equated to 100%. As such, we could compare CIs between different Boyden 
chambers and between pediatric controls and PCD patients.
Adhesion molecules activity assay. The downregulation of the selectin CD62L and the upregulation of 
selectin ligand CD15 on monocytes (gated on CD14 positivity) after stimulation was measured by flow cytometry, 
as previously described by Mortier et al.25. Whole blood of patients and healthy donors was diluted to 1 × 106 leu-
kocytes/ml in warm DPBS (37 °C). Leukocytes (500 µl/tube) were then stimulated with 10−8 M fMLP or 300 ng/
ml CCL2, both diluted in warm DPBS (37 °C). Stimulation with warm DPBS alone was used as control condition. 
The cells were incubated at 37 °C for 10 min. Activation was stopped by placing the cells on ice and adding 1 ml of 
ice-cold DPBS. After centrifugation (7 min, 1200 rpm, 4 °C), ice-cold FACS buffer was added and the cells were 
placed on ice for 15 min to block the Fc-receptors. Afterwards, the cells were stained with the following mono-
clonal antibodies, diluted in FACS buffer: PE-labeled anti-CD14, APC-labeled anti-CD62L and FITC-labeled 
anti-CD15. The cells were washed with FACS buffer and fixed with fixation buffer (vide supra) at 4 °C for 15 min. 
Red blood cells were removed with FACS lysing solution (BD Biosciences). Afterwards, the cells were washed 
once and subjected to flow cytometry (vide supra).
Phagocytosis assay. The phagocytic capacity of PBMCs was assessed by flow cytometry. PBMCs were 
diluted in phagocytosis uptake buffer (1.5 × 106 cells/ml; Live cell imaging solution, Molecular Probes, Eugene, 
Oregon) and Staphylococcus aureus labeled beads (pHrodo red S. aureus bioparticles; Molecular Probes) were 
added to the cells. These beads are sensitive to differences in pH and after uptake in acidic phagolysosomes, 
the fluorescence signal of the beads increases. The cells were incubated for 30 min (37 °C, 5% CO2) to stimulate 
phagocytic uptake of the beads (negative controls were incubated at 4 °C). Afterwards, the cells were washed twice 
with FACS buffer, fixed and evaluated by flow cytometry (vide supra).
Induction of cytokine production by PBMCs. Freshly isolated PBMCs were diluted in induction 
medium (2 × 106 c/ml; RPMI 1640 + 2% FBS + 0.01% gentamycin) and seeded in a 48-well plate. The cells were 
stimulated with the indicated concentrations of lipopolysaccharide (LPS; Sigma), peptidoglycan (PGN; Sigma), 
concanavalin A (conA), the dsRNA polyriboinosinic:polyribocytidylic acid (PIC; P-L Biochemicals, Milwaukee, 
WI) or recombinant human IL-1β at 37 °C and 5% CO2. After 24 h, the cell supernatants were collected, cleared 
from cells by centrifugation and stored at -20 °C. TNF-α, IL-1β, IL-10, CCL3, CCL5, CCL18 and CCL22 con-
centrations in the cell supernatants were determined by sandwich ELISA. The CCL3 ELISA is developed in our 
laboratory42. TNF-α, IL-1β, IL-10, CCL5, CCL18 and CCL22 DuoSet antibody pairs for ELISAs were purchased 
from R&D systems.
Statistical analysis. All data are expressed in median values, unless mentioned otherwise. Comparison 
between groups was performed with the non-parametric Mann-Whitney U-test (Graphpad Software 6, GraphPad 
Software, Inc., La Jolla, USA). A p-value < 0.05 was regarded as statistically significant.
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